Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Jul 28:14:503-507.
doi: 10.2147/IMCRJ.S323233. eCollection 2021.

Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy

Workagegnehu Hailu  1 , Tsebaot Tesfaye  1 , Abilo Tadesse  1
Affiliations
Case Reports

Hyperglycemia After Dolutegravir-Based Antiretroviral Therapy

Workagegnehu Hailu et al. Int Med Case Rep J. .

Abstract

Background: Antiretroviral therapies prolong life expectancy and improve the quality of life of HIV-infected patients. Despite the documented benefits of antiretroviral drugs, its use is not without side effects. Here, we report cases of new onset diabetes mellitus after taking a dolutegravir (DTG)-based ART regimen.

Case presentation: HIV-infected patients who had been on non-nucleoside reverse transcriptase inhibitor (NNRTI)-based ART regimens for more than a decade were shifted to integrase strand transfer inhibitors (dolutegravir)-based ART regimen as recommended by the National Comprehensive HIV Care Guideline. They were diagnosed to have diabetes mellitus with or without diabetic ketoacidosis (DKA) as evidenced by polyuria, polydipsia and fatigue, severe hyperglycemia (plasma glucose level >250 mg/dl) with or without ketonuria (3+) after 1-12 months of DTG-based ART regimen. Two of the patients who presented with DKA were treated with intravenous fluids and regular insulin. NPH insulin was started following recovery from DKA, which later shifted to metformin. One of the patients who presented with severe hyperglycemia without DKA was started with NPH insulin, which later shifted to metformin. Good glycemic control was obtained with metformin, while the DTG-based ART regimen was continued.

Conclusion: Hyperglycemia is a potential and noticed side effect of the DTG-based ART regimen. Baseline and periodic monitoring of plasma glucose might be required in ART regimens containing dolutegravir.

Keywords: INSTIs; dolutegravir; hyperglycemia.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest for this work.

References

    1. WHO Clinical Guidelines. Antiretroviral therapy; 2020. Avaialble from: http://www.who.int. Accessed July23, 2021.
    1. Ethiopia national consolidated guidelines for comprehensive HIV prevention, care and treatment; 2018. Avaialble from: http://www.afro.who.int. Accessed July23, 2021.
    1. Magdalena DI, Carmen CR, Rugina S. Dolutegravir efficacy in HIV infected patients. ARS Medica Tomitana. 2015;1(21):42–51.
    1. Phillips AN, Venter F, Havlir D, et al. Risks and benefits of dolutegravir-based antiretroviral drug regimens in Sub-Saharan Africa: a modeling study. Lancet. 2019;6(2):e116–27. doi:10.1016/S2352-3018(18)30317-5 - DOI - PMC - PubMed
    1. American Diabetes Association. Diabetes care: standards of medical care in diabetes-2020. J Clin Appl Res Educ. 2020;43(suppl–1):S1–S212.

Publication types

LinkOut - more resources